Where does the Paradigm Biopharmaceuticals share price go from here?

Paradigm Biopharmaceuticals Ltd (ASX: PAR): buy, hold, sell?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

At the start of April, the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price reached $2.02. Much of Paradigm's share price increase was in anticipation of secondary end point results for its phase 2b osteoarthritis trials.

The recent trial report showed extremely positive results.

Most importantly, it was found that Paradigm's repurposed drug showed a stark difference between itself and the placebo. The results were verified using an MRI scan which measured the lesion caused by bone marrow edema.

At day 53 of treatment, Paradigm's repurposed drug showed a reduced bone marrow lesion volume of 34% vs the placebos 3.6%. Furthermore, the bone marrow lesion area increased in the placebo group by 11.9% compared to a 25.3% decrease in the treatment group.

The objective results obtained were also statistically significant with a p-value of 0.03, meaning that it's highly likely that Paradigm's repurposed drug is causing the improvement of bone marrow lesions.

Why did the Paradigm share price not respond accordingly?

Despite fantastic secondary endpoint results from Paradigm, the share price did not react positively.

The cause can be attributed to Paradigm's capital raise at a significant discount which was announced alongside the secondary endpoint results.

Although Paradigm's share price could have responded better, Paradigm received strong attention for its $77.9 million capital raise which should be filled promptly.

Paradigm expects a cash level of $82 million post raise which will allow it to take its repurposed drug through phase 3 trials.

Additionally, a strong cash position by Paradigm will ensure a better offer from potential future negotiators.

At this stage, Paradigm is aware that it has a potential blockbuster drug on its hands and therefore wouldn't give it up without a significant premium.

Where does Paradigm go from here?

Paradigm has multiple share price catalysts coming up. These include the phase 2/3 clinical trials for MPS and the approval for selling its repurposed drug in Australia.

With the results obtained from its phase 2b trials, Paradigm has significantly de-risked its repurposed drug for phase 3.

Foolish takeaway 

Paradigm Biopharmaceuticals is currently well positioned to take its repurposed drug into phase 3 clinical trials. If Paradigm succeeds throughout phase 3, the share price could take off for many years to come.

For other growth companies, be sure to check out…

Motley Fool contributor Elton Wang owns shares of PARADIGM BIO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Young girl drinking milk showing off muscles.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a great end to the trading week for ASX investors today.

Read more »

Hands reaching high for a trophy with a sunset in the background.
Record Highs

The ASX 200 Index is on its way to another all-time high today. Here's why

These blue chip stocks are driving the index towards a new record today...

Read more »

Group of friends trading stocks on their phones. symbolising the 3 most traded ASX 200 shares today
Share Market News

3 ASX mining stocks topping the most-traded list in October

Chinese stimulus news and company announcements likely contributed to the higher trading activity.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Share Gainers

3 ASX 200 stocks smashing the benchmark this week

These three ASX 200 stocks are leading the charge this week. Here’s how.

Read more »

Two people tired and resting after sports race.
Broker Notes

Fundie rates 2 ASX 200 stocks in short-term pain but with long-term gain potential

Blackwattle Investment Partners sees these 2 ASX 200 stocks as worthy of a buy and hold strategy.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why A2 Milk, EOS, GQG, and Mineral Resources shares are racing higher today

These shares are ending the week strongly. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Megaport, Pilbara Minerals, Vysarn, and WiseTech shares are falling today

These shares are ending the week in the red. But why?

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »